The growing importance of glycans in biological processes is expanding research opportunities across diagnostics, drug discovery, personalized medicine, and biotechnology. The Glycomics Market was valued at USD 1.6 billion in 2022 and is projected to reach USD 4.9 billion by 2030, expanding at a CAGR of 14.6% from 2023 to 2030. The market is estimated to reach USD 2.8 billion in 2026, reflecting increasing investment in glycobiology research and the development of advanced analytical tools.

Download a free sample copy of the Glycomics market report to understand detailed coverage and inclusions in the final report

Market Breakdown at a Glance

The market covers enzymes, kits, reagents, and instruments across applications such as drug discovery & development and diagnostics. Academic and research institutes, biopharmaceutical companies, and other end users contribute to market expansion. Technological developments in glycomics instruments, increasing government research investments, and pharmaceutical and biotechnology companies' focus on novel drug development are among the factors supporting industry growth.

Market Dynamics & Segmentation

Enzymes represented the largest product segment, accounting for 29.2% of the market in 2022, and are expected to witness the fastest growth during 2023-2030. Their broad application in glycan-based research, diagnostics, and drug discovery supports continued demand. Advances in protein modification technologies and enzyme engineering are also enabling the development of more efficient and specific enzymes for glycomics applications.

Instruments represented the second-largest product segment with a 27.0% revenue share in 2022. Adoption is being supported by their increasing use in diagnostic testing and drug discovery, while improvements in accuracy and turnaround time are creating additional opportunities for advanced glycan-based instruments.

Drug discovery & development dominated the application landscape with a 42.3% market share in 2022. Rising R&D activities and government funding related to glycomics and proteomics are supporting this segment. Advanced glycan profiling and analytical techniques are helping researchers understand the role of glycans in identifying potential drug targets.

Diagnostics is projected to record the fastest application growth, with a CAGR of 14.9% during 2023-2030. Increasing demand for personalized medicine, the prevalence of chronic disorders, and developments in glycan analysis technologies are supporting this expansion. Glycan microarrays, mass spectrometry, and lectin-based assays have improved the detection specificity of glycan-based biomarkers.

Research Investment and Technology Development

Research investment remains an important element of market expansion. Government and non-profit funding has enabled researchers to develop new glycomics and glycobiology tools. GlycoNet received USD 16.3 million in funding in July 2020 to strengthen glycomic research for human health. The market is also benefiting from computational approaches. In September 2021, researchers at the University of California San Diego developed GlyCompare, an approach that enables glycomics datasets to be examined using AI and machine learning methods.

End-use Market Outlook

Academic and research institutes accounted for the largest end-use share, representing 38.2% in 2022. Extensive use of glycan structure data analysis, training, and educational applications contributes to this position. Glycomics products are also used across biomedical research, immunology, cell biology, biochemistry, and drug discovery & development.

Meanwhile, biopharmaceutical companies are projected to experience the fastest end-use growth at a 15.5% rate during the forecast period. Their efforts to develop advanced therapeutics and adopt glycan-based methodologies in drug development are supporting this expansion.

Regional Market Outlook

North America accounted for the largest market share at 39.1% in 2022, supported by developed economies, healthcare infrastructure, key market participants, advanced therapeutics demand, and government support for R&D. Europe is expected to witness the fastest market growth, supported by research infrastructure, universities, research institutes, grants, and funding programs.

Future Market Perspective

The combination of expanding glycobiology research, technological advancement, research funding, drug development activity, and applications in diagnostics is creating opportunities for continued market development. As analytical methods and glycomics tools advance, applications across drug discovery, diagnostics, biomedical research, and personalized medicine are expected to remain important areas of market activity.

FAQ

How big is the glycomics market?

The glycomics market was valued at USD 1.6 billion in 2022, is estimated at USD 2.8 billion in 2026, and is projected to reach USD 4.9 billion by 2030.

What trends are shaping the glycomics market?

Key developments include technological advancements in glycomics instruments, growing research investment, increasing use of glycomics in drug discovery and diagnostics, advances in glycan analysis, and the application of AI and machine learning to glycomics datasets.

Key Glycomics Companies:

Thermo Fisher Scientific, Inc.
Merck KgaA
Agilent Technologies Inc.
Bruker

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Enzymes Lead as Glycomics Market Growth Opens New Research Avenues

The global glycomics market size was valued at USD 1.6 billion in 2022 and is projected to grow from USD 2.8 billion in 2026 to USD 4.9 billion by 2030